BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 22316583)

  • 1. Assessing and measuring nonresponse in schizophrenia.
    Kane JM
    J Clin Psychiatry; 2012 Jan; 73(1):e04. PubMed ID: 22316583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transitioning from acute to long-term treatment in schizophrenia.
    Kane JM
    J Clin Psychiatry; 2011 Mar; 72(3):e10. PubMed ID: 21450146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-episode schizophrenia: the importance of early intervention and subjective tolerability.
    Kasper S
    J Clin Psychiatry; 1999; 60 Suppl 23():5-9. PubMed ID: 10625193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse prevention and recovery in the treatment of schizophrenia.
    Schooler NR
    J Clin Psychiatry; 2006; 67 Suppl 5():19-23. PubMed ID: 16822093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of treatment refractory schizophrenia.
    Morrison DP
    Br J Psychiatry Suppl; 1996 Dec; (31):15-20. PubMed ID: 8968651
    [No Abstract]   [Full Text] [Related]  

  • 6. Improving patient outcomes in schizophrenia: achieving remission, preventing relapse, and measuring success.
    Kane JM
    J Clin Psychiatry; 2013 Sep; 74(9):e18. PubMed ID: 24107769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of schizophrenia.
    Marder SR
    J Clin Psychiatry; 1996; 57 Suppl 3():9-13; discussion 47. PubMed ID: 8626371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic medication in the treatment of schizophrenia.
    Kane JM
    Isr J Psychiatry Relat Sci; 1995; 32(1):30-7. PubMed ID: 7542642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment.
    Altamura AC; Bobo WV; Meltzer HY
    Int Clin Psychopharmacol; 2007 Sep; 22(5):249-67. PubMed ID: 17690594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating clinical trial data: outcome measures.
    Conley RR
    J Clin Psychiatry; 2001; 62 Suppl 9():23-6; discussion 27-8. PubMed ID: 11379827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation.
    Leucht S; Davis JM; Engel RR; Kissling W; Kane JM
    Acta Psychiatr Scand Suppl; 2009; (438):7-14. PubMed ID: 19132961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors which can make patients difficult to treat.
    Kane JM
    Br J Psychiatry Suppl; 1996 Dec; (31):10-4. PubMed ID: 8968650
    [No Abstract]   [Full Text] [Related]  

  • 13. Maintaining symptom control: review of ziprasidone long-term efficacy data.
    Schooler NR
    J Clin Psychiatry; 2003; 64 Suppl 19():26-32. PubMed ID: 14728087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of treatment effects in schizophrenia.
    Stroup TS
    Am J Med; 2007 Apr; 120(4 Suppl 1):S26-31. PubMed ID: 17403379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia.
    Nasrallah HA; Tandon R
    J Clin Psychiatry; 2002; 63 Suppl 13():12-20. PubMed ID: 12562142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
    Buckley PF
    Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sertindole: a review of clinical efficacy.
    Kane JM
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S59-63; discussion S63-4. PubMed ID: 9690972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolving definition of treatment resistance.
    Peuskens J
    J Clin Psychiatry; 1999; 60 Suppl 12():4-8. PubMed ID: 10372602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
    Lasser RA; Bossie CA; Zhu Y; Gharabawi G; Eerdekens M; Davidson M
    Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.